The global search for a vaccine has entered a new chapter — and Australia is manoeuvring This week, the global search for one of the most important medical prizes ever entered a new chapter. The UK's Oxford University, considered one of the leaders in the search for a COVID-19 vaccine, announced its candidate is safe and has produced an immune response in early-stage clinical trials. The UK Government has committed to producing 100 million doses of the Oxford vaccine candidate, if it is successful. Australia's wait-and-see approach Australia has invested $5 million in the University of Queensland (UQ) vaccine candidate — which entered into human trials earlier this month — and Australian manufacturer CSL hopes to produce up to 100 million doses of a COVID-19 vaccine by the end of next year, if it is successful. The Government has also invested a further $14 million to help with vaccine development, and claims it has spent $256 million in "vaccine-related activity". There are now more than 200 COVID-19 vaccine candidates across the world, with 22 in clinical trials. Australians would be first in line to receive the UQ vaccine, but no formal commercial arrangement like the UK's has yet been announced by the Australian Government. And according to vaccine expert and Federal Government adviser Tony Cunningham, the UK's broader strategy of looking at multiple vaccines is something the Government needs to consider.